The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

Nov. 17, 2016
Applicants:

Massachusetts Eye and Ear Infirmary, Boston, MA (US);

The Regents of the University of California, Oakland, CA (US);

Inventors:

Kip M. Connor, Newton, MA (US);

Eiichi Hasegawa, Fukuoka, JP;

Bruce D. Hammock, Davis, CA (US);

Kin Sing Stephen Lee, Davis, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/17 (2006.01); A61K 31/202 (2006.01); A61K 31/336 (2006.01); A61K 31/445 (2006.01); A61K 31/4468 (2006.01); A61P 27/02 (2006.01); A61P 27/04 (2006.01); A61P 27/06 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/336 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 31/17 (2013.01); A61K 31/202 (2013.01); A61K 31/445 (2013.01); A61P 27/02 (2018.01); A61P 27/04 (2018.01); A61P 27/06 (2018.01); A61K 31/4468 (2013.01); A61K 2300/00 (2013.01);
Abstract

This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).


Find Patent Forward Citations

Loading…